Sector News

Catherine M. Burzik joins Haemonetics Board of Directors

October 28, 2016
Life sciences

Haemonetics Corporation announced the election of Catherine M. Burzik, a highly respected and accomplished senior executive in the healthcare industry, to its Board of Directors. Ms. Burzik successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses.

Richard J. Meelia, Chairman of Haemonetics’ Board of Directors commented, “Cathy Burzik brings extensive experience as a superb operator and a highly effective value creator in the healthcare industry. She has demonstrated the ability to apply innovative and strategic direction, leading to the creation of significant shareholder value. We welcome her and look forward to her contribution to our Company’s success.”

“Haemonetics’ products and services address the key focal points of the health care industry – providing the best possible clinical outcomes for clinicians and their patients, while managing cost structures.” said Ms. Burzik. “I look forward to joining the Board of Directors and serving the Company’s shareholders.”

Until the sale of the company in 2012, she served as President, Chief Executive Officer and Director of Kinetic Concepts, Inc., a medical device company specializing in wound care and regenerative medicine. Her prior positions include President of Applied Biosystems Group, a pioneer DNA sequencing company, President of Ortho Clinical Diagnostics and Critikon divisions of Johnson & Johnson and senior positions with MITRE Corporation and Eastman Kodak Company.

Ms. Burzik currently serves on the Boards of Directors of Becton Dickinson & Company and Xenex Disinfection Services LLC, , and is non-executive chairman of the Board of Directors of StemBioSys, Inc. She previously served on the Boards of Directors of Allscripts, Bausch and Lomb, Cordis Corporation, the San Antonio Branch of the Dallas Federal Reserve Board, Innovative Trauma Care Ltd., Kinetic Concepts, Inc., and VitaPath Genetics, Inc.

Ms. Burzik is currently a general partner with Targeted Technology Fund II, a fund within Targeted Technologies LLC, an early stage venture capital firm focused on medical device, life sciences and biotech investments. She is also Founder and CEO of the Catherine and Francis Burzik Foundation and has served on a number of non-profit boards. Her education includes a Bachelor’s in Mathematics from Canisius College and a Master’s in Mathematics from the University of Buffalo.

Source: Haemonetics

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).